Status:
NOT_YET_RECRUITING
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
Lead Sponsor:
Ausper Biopharma Co., Ltd.
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18+ years
Brief Summary
This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 inj...
Eligibility Criteria
Inclusion
- Capable of giving informed consent.
- Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.
Exclusion
- Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137.
- Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.
Key Trial Info
Start Date :
August 21 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2030
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07146100
Start Date
August 21 2025
End Date
January 1 2030
Last Update
August 28 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
AusperBio Investigational Site
Guangzhou, Guangdong, China
2
AusperBio Investigational Site
Changchun, Jilin, China